Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samuel Chantilis

Reproductive Endocrinology Dallas, TX Medical Doctor

NPI 1386696052 CMS profile 17028

8160 Walnut Hill Ln, Suite 328, Dallas, TX 75231

Open in the dashboard

General payments

$2,597

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samuel Chantilis of Dallas, TX is reported in the CMS Open Payments database as having received $2,597 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Reproductive Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $197 10
2024 General $235 9
2023 General $139 8
2022 General $579 15
2021 General $379 9
2020 General $324 10
2019 General $743 22

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samuel Chantilis
  • Reproductive Endocrinology median
  • Middle half of Reproductive Endocrinology
  • National median

In program year 2025, general payments to Samuel Chantilis were reported at $197. Among 986 Reproductive Endocrinology profiles paid that year, the median was $141 and the middle half received between $66 and $285.

Show as a table
Year Samuel Chantilis Reproductive Endocrinology median Middle half National median
2019 $743 $196 $77–$425 $163
2020 $324 $81 $35–$182 $114
2021 $379 $102 $43–$247 $132
2022 $579 $139 $62–$303 $149
2023 $139 $141 $65–$285 $160
2024 $235 $144 $65–$302 $164
2025 $197 $141 $66–$285 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperSurgical, Inc. $905 14 payments
  2. Organon LLC $361 22 payments
  3. Vitrolife Inc. $350 2 payments
  4. Ferring Pharmaceuticals Inc. $248 14 payments
  5. EMD Serono, Inc. $172 10 payments
  6. Covidien LP $151 1 payment
  7. Merck Sharp & Dohme Corporation $105 6 payments
  8. Caldera Medical, Inc $90 1 payment
  9. AbbVie, Inc. $68 4 payments
  10. Meditrina $58 4 payments
  11. Other $89 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,577 82 payments
  2. Education $20 1 payment
Products named General payments · program years 2019–2025
  1. IVF Products Devices $558 8 payments
  2. FOLLISTIM AQ Follitropin $377 18 payments
  3. PREGNYL $266 16 payments
  4. GANIRELIX ACETATE $233 13 payments
  5. IVF Products Devices $190 2 payments
  6. TruClear $151 1 payment
  7. MENOPUR Reproductive Health $142 9 payments
  8. MENOPUR Reproductive Health $106 5 payments
  9. FOLLISTIM AQ Womens Health $105 6 payments
  10. STRIPPER $92 1 payment
  11. Other $488 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Reproductive Endocrinology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record